Vaxcyte (NASDAQ: PCVX) SVP granted options, RSUs and surrenders shares for taxes

Rhea-AI Filing Summary

Vaxcyte, Inc. reported insider equity transactions by Elvia Cowan, its SVP, Finance & CAO. On February 26, 2026, Cowan received a grant of stock options for 17,855 shares and a separate award of 10,681 restricted stock units, each RSU representing one share of common stock.

The RSUs vest as to one quarter of the shares on September 7, 2026, then one eighth every six months, subject to continued service. The new option vests as to one forty-eighth of the shares on March 26, 2026, and monthly thereafter, also subject to continued service.

On the same date, Cowan exercised 7,716 stock options at $25.92 per share, receiving the same number of common shares. On February 28 and March 2, 2026, a total of 569 shares were surrendered at $61.98 per share to cover tax withholding on vested RSUs. After these transactions, Cowan directly owned 31,362 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cowan Elvia

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance & CAO

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		10,681(1)	A	$0	24,215	D
Common Stock	02/26/2026		M		7,716	A	$25.92	31,931	D
Common Stock	02/28/2026		F		243(2)	D	$61.98	31,688	D
Common Stock	03/02/2026		F		326(2)	D	$61.98	31,362	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$60	02/26/2026		A		17,855		(3)	02/26/2036	Common Stock	17,855	$0	17,855	D
Stock Option (right to buy)	$25.92	02/26/2026		M			7,716	(4)	08/08/2032	Common Stock	7,716	$0	98,568	D

Explanation of Responses:

1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

2. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

3. 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

4. 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Remarks:

	Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Vaxcyte (PCVX) report for Elvia Cowan?

Vaxcyte reported that Elvia Cowan received new stock option and RSU awards, exercised existing options, and surrendered shares for tax withholding. These combined transactions changed her direct common stock holdings and outlined a multi‑year equity vesting schedule tied to ongoing service.

How many stock options did the Vaxcyte (PCVX) SVP receive in this Form 4?

Elvia Cowan received a grant of stock options covering 17,855 shares of Vaxcyte common stock. One forty-eighth of these options vest on March 26, 2026, with additional one forty-eighth installments vesting monthly thereafter, contingent on her continued service with the company.

What are the key vesting terms for the Vaxcyte (PCVX) RSU award reported?

The RSU award covers 10,681 shares of Vaxcyte common stock. One quarter of the RSUs vest on September 7, 2026, and one eighth of the shares vest every six months after that, provided Elvia Cowan remains continuously employed by Vaxcyte through each vesting date.

Did the Vaxcyte (PCVX) executive exercise any stock options in this filing?

Yes. On February 26, 2026, Elvia Cowan exercised stock options for 7,716 shares of Vaxcyte common stock at an exercise price of $25.92 per share. The exercised options converted into the same number of common shares held directly after the transaction.

Why were Vaxcyte (PCVX) shares surrendered by Elvia Cowan in this Form 4?

Shares were surrendered to cover tax withholding obligations triggered by RSU vesting. Specifically, 243 shares on February 28, 2026, and 326 shares on March 2, 2026, were delivered back to Vaxcyte at $61.98 per share to satisfy those tax liabilities.

What is Elvia Cowan’s reported Vaxcyte (PCVX) share ownership after these transactions?

Following the reported grants, exercises, and tax-withholding surrenders, Elvia Cowan directly owned 31,362 shares of Vaxcyte common stock. This figure reflects her holdings after the March 2, 2026 transaction, as disclosed in the Form 4 ownership totals.